BACKGROUND: Vemurafenib, a BRAF inhibitor, is a first-line treatment for inoperable melanoma. Sarcoidosis has never been reported in patients on vemurafenib. OBJECTIVES: We describe 5 cases of sarcoidosis in patients treated with vemurafenib. METHODS: Seventy patients receiving vemurafenib for a BRAF-mutated inoperable stage III or IV melanoma were treated in our centre. RESULTS: Five patients (7.1%) developed sarcoidosis or a sarcoid-like reaction on vemurafenib; 4 patients had cutaneous signs and 3 had extracutaneous disorders (bilateral hilar lymph nodes, uveitis). Histological analysis of skin lesions revealed epithelioid granulomas without necrosis, consistent with sarcoidosis. Angiotensin-converting enzyme levels were high in 2 patients. Cutaneous and ophthalmological lesions rapidly disappeared on topical corticosteroid treatment without the cessation of vemurafenib treatment. Complete remission of melanoma was observed in 3 patients and partial remission was observed in another. CONCLUSION: BRAF inhibitors probably have immune system-enhancing effects and should therefore be recognized as potential inducers of sarcoidosis.
BACKGROUND:Vemurafenib, a BRAF inhibitor, is a first-line treatment for inoperable melanoma. Sarcoidosis has never been reported in patients on vemurafenib. OBJECTIVES: We describe 5 cases of sarcoidosis in patients treated with vemurafenib. METHODS: Seventy patients receiving vemurafenib for a BRAF-mutated inoperable stage III or IV melanoma were treated in our centre. RESULTS: Five patients (7.1%) developed sarcoidosis or a sarcoid-like reaction on vemurafenib; 4 patients had cutaneous signs and 3 had extracutaneous disorders (bilateral hilar lymph nodes, uveitis). Histological analysis of skin lesions revealed epithelioid granulomas without necrosis, consistent with sarcoidosis. Angiotensin-converting enzyme levels were high in 2 patients. Cutaneous and ophthalmological lesions rapidly disappeared on topical corticosteroid treatment without the cessation of vemurafenib treatment. Complete remission of melanoma was observed in 3 patients and partial remission was observed in another. CONCLUSION:BRAF inhibitors probably have immune system-enhancing effects and should therefore be recognized as potential inducers of sarcoidosis.
Authors: Francesco Facchinetti; Letizia Gnetti; Valeria Balestra; Mario Silva; Enrico Maria Silini; Luigi Ventura; Maria Majori; Paola Bordi; Marcello Tiseo Journal: Invest New Drugs Date: 2018-08-01 Impact factor: 3.850
Authors: Nidhi Shah; Monica Shah; Aaron M Drucker; Neil H Shear; Michael Ziv; Roni P Dodiuk-Gad Journal: Am J Clin Dermatol Date: 2021-01 Impact factor: 7.403
Authors: Joshua E Reuss; Paul R Kunk; Anne M Stowman; Alejandro A Gru; Craig L Slingluff; Elizabeth M Gaughan Journal: J Immunother Cancer Date: 2016-12-20 Impact factor: 13.751
Authors: Florentia Dimitriou; Anna L Frauchiger; Mirjana Urosevic-Maiwald; Mirjam C Naegeli; Simone M Goldinger; Marjam Barysch; Daniel Franzen; Jivko Kamarachev; Ralph Braun; Reinhard Dummer; Joanna Mangana Journal: Melanoma Res Date: 2018-06 Impact factor: 3.599